Screener
Rhythm Pharmaceuticals, Inc. RYTM Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 80,045 | 83,855 |
| Lease liability | 676 | 650 |
| Deferred revenue | 48 | 194 |
| Deferred royalty obligation, current | 10,130 | 7,296 |
| Total current liabilities | 103,198 | 105,942 |
| Long-term liabilities: | ||
| Deferred royalty obligation | 98,339 | 100,886 |
| Lease liability, non-current | 3,163 | 3,342 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s current debt?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported current debt of $10.13M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s current debt changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s current debt increased by 537.1% year-over-year, from $1.59M to $10.13M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude